LAVA Therapeutics (NASDAQ:LVTX – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.15, MarketWatch Earnings reports. LAVA Therapeutics had a negative return on equity of 51.14% and a negative net margin of 167.49%.
LAVA Therapeutics Stock Down 0.7 %
NASDAQ LVTX opened at $1.48 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.31 and a current ratio of 5.31. LAVA Therapeutics has a twelve month low of $1.13 and a twelve month high of $7.38. The stock’s 50 day moving average is $1.44 and its 200 day moving average is $1.74.
Institutional Investors Weigh In On LAVA Therapeutics
Several hedge funds have recently added to or reduced their stakes in the stock. Bruce & Co. Inc. purchased a new position in shares of LAVA Therapeutics in the fourth quarter worth $350,000. PNC Financial Services Group Inc. increased its position in LAVA Therapeutics by 30.0% during the second quarter. PNC Financial Services Group Inc. now owns 65,000 shares of the company’s stock valued at $132,000 after acquiring an additional 15,000 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in LAVA Therapeutics during the fourth quarter valued at $66,000. Finally, Bank of America Corp DE increased its position in LAVA Therapeutics by 20,566.7% during the first quarter. Bank of America Corp DE now owns 32,240 shares of the company’s stock valued at $54,000 after acquiring an additional 32,084 shares during the last quarter.
Analyst Ratings Changes
LAVA Therapeutics Company Profile
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
- Five stocks we like better than LAVA Therapeutics
- What Is WallStreetBets and What Stocks Are They Targeting?
- Williams-Sonoma is a steal for buy-and-hold investors
- 3 Warren Buffett Stocks to Buy Now
- A closer look at Warren Buffett’s latest surprise purchase
- What Does the Consumer Price Index Measure?
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.